An Organ-on-a-Chip Model of ALS Will Help Uncover Early Disease Characteristics and Find Potential Therapies

August 6, 2025

Microscopic image of motor neurons and axons in an ALS organ chip.

Motor neurons and their axons labeled in green, are growing on a spinal cord organ-chip developed by Cedars-Sinai. (Svendsen Laboratory)

A neurodegenerative disorder known as amyotrophic lateral sclerosis (ALS) causes paralysis and is usually fatal within two to five years. Motor neurons (MNs) send signals from the brain and spinal cord to the body; they control normal functions, such as breathing, talking and walking. The hallmark feature of ALS is permanently damaged MNs. About 90% of ALS cases have an unknown origin, and the disease is not passed down from parents. Part of what’s hindered our understanding of ALS is that current cell culture models of ALS are limited and do not effectively mimic key traits of human physiology.

A recent study at Cedars-Sinai supported by NCATS’ Tissue Chip for Drug Screening program focused on creating a three-dimensional cell culture model — an organ-on-a-chip — of ALS. Researchers have called it the spinal cord chip (SC-chip). The SC-chip grows MNs and endothelial cells (cells that line blood vessels and regulate blood flow) together in parallel chambers of a miniaturized chip known as a microfluidic device. These chambers are separated by a membrane that allows fluid to pass through, enabling nutrients to be absorbed and cell waste to be removed, which keeps the cells alive and mimics the human blood-brain barrier. Researchers isolated cells that become MNs from healthy (control) patients and from ALS patients to grow in the SC-chips. Compared with standard two-dimensional cell cultures of MNs, SC-chips provide an environment for MNs to closely mimic what is seen within a living organism, which makes them useful for advancing human health. SC-chip analysis showed that MNs isolated from ALS patients had unique changes in the amount of molecules related to neurofilaments, glutamatergic signaling, and synapse activity compared with MNs from control patients.

Using the SC-chip, future studies will explore the underlying causes of ALS, advance understanding of the disease’s progression, and provide a human-relevant model for drug screening of possible therapies for ALS patients. Danilo A. Tagle, Ph.D., director of NCATS’ Office of Special Initiatives, stated, “The result from this important study lays the groundwork for investigating the role of increased glutamate signaling in the gradual death of motor neurons in ALS, and provides opportunities to screen for interventions.”

The results appeared in Cell Stem Cell .